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Context. To improve the management of cancer-related symptoms, systematic
screening is necessary, often performed by using 0e10 numeric rating scales. Cut
points are used to determine if scores represent clinically relevant burden.
Objectives. The aim of this systematic review was to explore the evidence on cut
points for the symptoms of the Edmonton Symptom Assessment Scale.
Methods. Relevant literature was searched in PubMed, CINAHL, Embase, and
PsycINFO. We defined a cut point as the lower bound of the scores representing
moderate or severe burden.
Results. Eighteen articles were eligible for this review. Cut points were
determined using the interference with daily life, another symptom-related
method, or a verbal scale. For pain, cut point 5 and, to a lesser extent, cut point 7
were found as the optimal cut points for moderate pain and severe pain,
respectively. For moderate tiredness, the best cut point seemed to be cut point 4.
For severe tiredness, both cut points 7 and 8 were suggested frequently. A lack of
evidence exists for nausea, depression, anxiety, drowsiness, appetite, well-being,
and shortness of breath. Few studies suggested a cut point below 4.
Conclusion. For many symptoms, there is no clear evidence as to what the
optimal cut points are. In daily clinical practice, a symptom score $4 is
recommended as a trigger for a more comprehensive symptom assessment. Until
there is more evidence on the optimal cut points, we should hold back using
a certain cut point in quality indicators and be cautious about strongly
recommending a certain cut point in guidelines. J Pain Symptom Manage
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Introduction
Cancer patients suffer from many physical
and psychological symptoms, negatively affect-
ing quality of life and daily activities.1 To
improve the management of these cancer-
related symptoms, it is necessary to screen for
these symptoms systematically. Many screening
instruments measure the intensity of symp-
toms on a 0e10 numeric rating scale (NRS),
in which 0 means ‘‘no suffering’’ and 10 means
‘‘unbearable suffering.’’2e4
Before being able to interpret the results of
these measurements, it is important to deter-
mine the clinical meaning of the scores given
on the 0e10 NRS for the various symptoms.
NRS scores have been categorized as none,
mild, moderate, and severe5 or as representing
clinically relevant burden or not.6 When studies
categorize NRS scores as none, mild, moderate,
and severe, they report two cut points: one cut
point for the boundary between mild and mod-
erate burden and another cut point for the
boundary betweenmoderate and severe burden.
In case articles report one cut point for clinically
relevant burden, they describe it as a clinically
significant cut point, an optimal single cut point,
or a cut point for significant burden. The cut
point for clinically relevant burden is considered
to be equivalent to the cut point between mild
and moderate burden.6
Cut points are frequently used in research
and in daily clinical practice. For example,
cut points are frequently used in inclusion
criteria and in the definition of end points of
clinical trials. Furthermore, they are used in
quality indicators to measure the quality of
care. In addition, cut points are recommended
in guidelines as a starting point for the initia-
tion of treatment and for the evaluation of
the treatment7 (e.g., National Comprehensive
Cancer Network [NCCN] guidelines8,9).
For various symptoms, cut points on the NRS
have been proposed, especially for pain and fa-
tigue.6,10 However, there is heterogeneity in the
cut points being recommended. For example,
theNCCNproposed a cut point$4 for fatigue,8
whereas an expert group of the European Asso-
ciation for Palliative Care suggested the cutpoint $5. Despite this lack of uniformity, as
mentioned before, cut points are advised in
guidelines and quality indicators, which has
consequences for the treatment of the symp-
toms and the assessment of the quality of care.
Therefore, it is important to define evidence-
based cut points that are proven to distinguish
between NRS scores with clinically relevant bur-
den or not. The aimof this reviewwas to explore
the evidence on cut points for the respective
symptoms of the Edmonton Symptom Assess-
ment Scale (ESAS) in cancer patients and
whether it is possible to recommend an optimal
cut point per symptom or to recommend one
cut point for all symptoms of the ESAS.Methods
We conducted a systematic review on cut
points for the symptoms of the ESAS: pain, tired-
ness, nausea, depression, anxiety, drowsiness, ap-
petite, well-being, and shortness of breath. We
searched for studies that measured these symp-
toms on an NRS or an equivalent instrument,
that is, a visual analogue scale (VAS),12 the Brief
Pain Inventory (BPI),13 the Brief Fatigue Inven-
tory (BFI),14 the ESAS,2 the M. D. Anderson
Symptom Inventory,3 the Fatigue Symptom In-
ventory,15 or the Symptom Monitor.4
Relevant literature was searched in PubMed,
using the search strategy: ‘‘Neoplasms’’[Mesh]
AND (cutOR cut-offOR ‘‘cut off’’ OR cutpoint*
OR ‘‘symptom severity’’) AND (symptom OR VAS
OR ‘‘Visual Analogue Scale’’ OR ‘‘Visual Analog
Scale’’OR ‘‘Visual Scale’’ORNRSOR ‘‘Numeric
Rating Scale’’ OR BPI OR ‘‘Brief Pain Inven-
tory’’ OR BFI OR ‘‘Brief Fatigue Inventory’’
ORESASOR ‘‘Edmonton SymptomAssessment
Scale’’ OR FSI OR ‘‘Fatigue Symptom Inven-
tory’’OR ‘‘M.D. Anderson Symptom Inventory’’
OR ‘‘symptommonitor’’). We used this strategy
for the nine symptoms of the ESAS and also in-
cluded the synonyms used by the revised
ESAS:16 pain, tiredness (including fatigue and
lack of energy), nausea, depression (including
feeling sad), anxiety (including nervousness
and feeling nervous), drowsiness (including
sleepiness and feeling sleepy), appetite
Vol. 45 No. 6 June 2013 1085Cut Points for Symptoms Included in the ESAS in Cancer Patients(including loss of appetite, lack of appetite,
poor appetite, and anorexia), well-being, and
shortness of breath (including dyspnea and
breathlessness).
The search was limited to English articles
published until July 2011 and to original
articles. Studies were included in this review
if they were performed with cancer patients,
measured one or more symptoms of the
ESAS on a 0e10 NRS, and performed statisti-
cal tests to determine the optimal cut point.
To identify supplementary studies, we studied
the reference lists of the selected articles and
searched for cross-references. We conducted
an additional search in CINAHL, Embase,
and PsycINFO using the same search strategy.
Articles were reviewed for eligibility indepen-
dently by two authors (W. H. O. and P. J. d. R.).
The results were summarized, and conclusions
were independently drafted by these two au-
thors. If the reviewers disagreed about a conclu-
sion, the assumptions leading to the conclusion
were discussed until consensus was reached.
Per study, we reported patient characteristics
(e.g., disease stage, antitumor treatment), in-
clusion criteria with respect to symptom scores,
methodological characteristics, and quality cri-
teria (e.g., prospective or retrospective design,
if a primary or secondary analysis was per-
formed, sample size), specification of the type
of symptom intensity asked for (e.g., usual,
worst), the method used to determine the cut
point, and the number of optional cut points
explored. We studied which NRS scores were
tested as possible cut points for the various
symptoms and which scores were finally se-
lected as the most optimal cut points.
In some articles, the reported cut point
reflected the lower bound of a category,14
whereas in other studies the reported cut point
represented the upper bound of a category.5
We chose to report the lower bound of a cate-
gory as the cut point. For example, when we re-
port cut points 5 and 7 (CP57), we mean that
mild burden is defined with scores 1e4, mod-
erate burden is defined with scores 5e6, and
severe burden is defined with scores 7e10.Results
We found 1524 articles through the original
search, of which 14 were relevant. Theadditional search produced four supplemen-
tary articles. In total, we found 18 relevant arti-
cles that determined cut points for symptoms
covered by the ESAS (Fig. 1). The main charac-
teristics and the quality aspects of these articles
are summarized in Tables 1 and 2. The major-
ity of the studies included patients with various
stages of cancer; five studies only included pa-
tients with advanced cancer.5,10,17e19 In seven
articles, patients were only eligible when they
met a certain inclusion criterion on symptom
burden.5,6,19e23 Four articles determined cut
points for multiple symptoms.6,10,21,24 Six stud-
ies were primarily designed to calculate cut
points.6,10,23,25e27 All studies measured the
symptom on a 0e10 NRS, and no studies
used a VAS. For pain, all studies defined the
type of symptom intensity (e.g., worst or usual)
they asked for. Four of 10 studies on fa-
tigue10,18,21,26 and all studies on the other
symptoms did not define the type of symptom
intensity (Table 2). The recall time of the ques-
tion about symptom intensity varied between
‘‘right now’’10 to ‘‘last week.’’5 Seven studies
did not describe the recall time.17,19e21,23,24,26
Methods Used to Determine Cut Points
Fifteen studies determined the cut point
for a certain symptom using the interference
of that symptom with daily life as ref-
erence.5,6,14,17e23,25,27e30 Three studies used
another symptom-related questionnaire as ref-
erence,6,24,26 and one study assessed the cut
point using the severity of that particular symp-
tom on a verbal scale (none, mild, moderate,
severe) as reference10 (Table 2).
Twelve studies described two cut points: a cut
point formild/moderate burdenanda cut point
formoderate/severeburden.5,10,14,17,19e21,25,27e30
The other studies assessed one cut point for
clinically relevant burden6,18,22e24,26 (Table 2).
Studies used regression models or a receiver
operating characteristic (ROC) curve to deter-
mine the optimal cut point(s). The studies us-
ing regression models (multivariate analysis of
variance [MANOVA] or general linear model
[GLM]) studied multiple cut points or combi-
nations of cut points to categorize NRS scores
by symptom severity (clinically relevant/not
clinically relevant or mild/moderate/severe).
The cut point or combination of cut points
that best differentiated the symptom severity
categories with respect to the level the
Fig. 1. Flowchart of selection process.
1086 Vol. 45 No. 6 June 2013Oldenmenger et al.symptom interfered with daily life, as mea-
sured with the reference questionnaire, was
considered to be the optimal cut point. The
number of possible options explored for a sin-
gle cut point varied from one25 to seven.17
The studies using an ROC curve predefined
per patient if a symptom was present, using
a reference questionnaire. Thereafter, for
each possible cut point on the NRS, the sensi-
tivity and specificity were calculated. The sensi-
tivity was defined as the proportion of the
patients suffering from that particular symp-
tom (as predefined using the reference ques-
tionnaire) with an NRS score on that possible
cut point or higher. The specificity was definedas the proportion of the patients not suffering
from that particular symptom (according to
the reference questionnaire) with an NRS
score below that possible cut point. The opti-
mal cut point is that with the optimal ratio be-
tween sensitivity and specificity.
Optimal Cut Points per Symptom
Pain. Ten studies assessed cut points on an
NRS for pain.5,6,10,17,19,21e23,28 Pain was asked
as present pain,10,17 average pain,17,19,21,23 or
worst pain.5,6,17,19,20,22,28 Seven studies used
a MANOVA5,17,19,20,22,23,28 and one study
a GLM,21 both with the interference items of
the BPI as reference. In the seven studies
Table 1
Overview of the Characteristics of the Included Studies
First Author (Year) Symptoms Study Design Type of Analysis
Patient Population
N Disease Stage (%) Treatment (%)
Symptom Burden in
Inclusion Criteria
Serlin5 (1995) Pain Retrospective Secondary 1897 Metastatic (100) ? Worst pain >0
Mendoza14 (1999) Fatigue Prospective Secondary 305 Advanced (85)
Early (15)
CT (100) d
Okuyama18 (2001) Fatigue Prospective Secondary 157 Advanced lung cancer d d
Hwang25 (2002) Fatigue Prospective Primary 180 NED (7)
Localized (5)
Locally advanced (21)
Advanced (67)
CT (17)
RT (10)
CRT (4)
HT (22)
None (47)
d
Okuyama30 (2003) Fatigue Prospective Secondary 252 Recurrence (36)
Metastatic (50)
Surgery (2)
CT (22)
RT (2)
d
Paul19 (2005) Pain Retrospective Secondary 160 Metastatic (100) CT (46)
HT (32)
RT (18)
BT (3)
None (12)
Average pain $2.5
Temel26 (2006) Fatigue Prospective Primary 574 ? ? d
Vignaroli24 (2006) Depression, anxiety Retrospective Secondary 216 ? ? ?
Chang27 (2007) Fatigue Prospective Primary 150 I (10)
II (9)
III (23)
IV (58)
Surgery (15)
CT (66)
RT (27)
None (21)
d
Li17 (2007) Pain Retrospective Secondary 199 Metastatic (100) RT (100) d
Butt6 (2008) Pain, fatigue, appetite loss Prospective Primary 148 Local (27)
Regional (24)
Metastatic (42)
N/A (7)
? NRS $4 on $1/4 symptoms
Given21 (2008) Pain, fatigue, nausea, depression,
anxiety, poor appetite, dyspnea
Retrospective Secondary 588 Early (15)
Late (85)
CT (100) NRS $2 on $1/16 symptoms
Kalyadina28 (2008) Pain Prospective Secondary 148 I or II (7)
III (52)
IV (35)
Recurrent disease (6)
? d
Valeberg23 (2008) Pain Prospective Primary 210 Metastatic (41) ? Average pain $0
Utne22 (2009) Pain Retrospective Secondary 225 Metastatic (70) ? Opioid treatment
Mendoza29 (2010) Fatigue Prospective Secondary 206 ? ? d
Selby10 (2010) Pain, tiredness, nausea, depression,
anxiety, drowsiness, loss of appetite,
well-being, shortness of breath
Prospective Primary 400 Advanced ? d
Ferreira20 (2011) Pain Prospective Secondary 143 Metastatic (66) None (100) Chronic cancer-related pain
CT¼chemotherapy; NED¼ no evidence of disease; RT¼radiation therapy; CRT¼chemoradiation therapy; HT¼ hormonal therapy; BT¼ biotherapy; NRS¼ numeric rating scale; N/A¼ not applicable (i.e.,
patients with hematologic malignancies).
V
ol.
4
5
N
o.
6
Ju
n
e
2
0
1
3
1
0
8
7
C
u
t
P
oin
ts
for
Sym
ptom
s
In
clu
ded
in
the
E
SA
S
in
C
an
cer
P
atien
ts
Table 2
Cut Points per Symptom
First Author (Year) N
Source
of NRS Question Recall Time
Reference
Statistical
Method
NRS Score
Type
Question-
naire Cut Point 1 2 3 4 5 6 7 8 9 10
Pain
Li17 (2007) 199 BPI Pain (present)a Now Interference BPI-I d MANOVA Mob Mob,c Mob,c Mob,c Sb,c Sb,c Sb,c Sc
Selby10 (2010) 400 ESAS Pain (present) Now Verbal Scale VRS Mo or S ROC curve Mo Mo S S S S
Paul19 (2005) 160 BPI Pain (average) ? Interference BPI-I d MANOVA b Mob Mob,c Moc S S S
Li17 (2007) 199 BPI Pain (average)a ? Interference BPI-I d MANOVA b b,c Mob,c Mob,c Sb,c Sb,c Sb,c Sc
Given21 (2008) 588 Seven-itemd Pain (average) ? Interference BPI-Ie d GLM Mo Mo Mo S S S S S S
Valeberg23 (2008) 210 BPI Pain (average) ? Interference BPI-I d MANOVA b CRb CRb CRb CRb CRb CR
Serlin5 (1995) 1897 BPI Pain (worst) Seven days Interference BPI-I d MANOVA b Mob Mo Sc Sc S S
Paul19 (2005) 160 BPI Pain (worst) ? Interference BPI-I d MANOVA b Mob Mob,c Moc Sc S S
Li17 (2007) 199 BPI Pain (worst)a ? Interference BPI-I d MANOVA b b,c Mob,c Mob,c Sb,c Sb,c Sb,c Sc
Butt6 (2008) 148 Four-itemf Pain (worst) Three days Interference BPI-I BPI-I $45 ROC curve CR CR CR CR CR CR CR
Kalyadina28 (2008) 148 BPI Pain (worst) 24 hours Interference BPI-I d MANOVA b Mob Mo Sc Sc S S
Utne22 (2009) 225 BPI Pain (worst) 24 hours Interference BPI-I d MANOVA b CRb CRb CRb CR CR CR
Ferreira20 (2011) 143 BPI Pain (worst) ? Interference BPI-I d MANOVA b Mob Mob,c Moc Sc S S
Tiredness
Selby10 (2010) 400 ESAS Tiredness Now Verbal Scale VRS Mo or S ROC curve Mo Mo S S S
Okuyama18 (2001) 157 One-item Fatigue 24 hours Interference BFI-I $1 item $1 ROC curve CR CR CR CR CR CR CR CR
Temel26 (2006) 574 One-item Fatigue ? Symptom
Scale
FACT-F FACT-F <30 ROC curve CR CR CR CR CR CR CR
Given21 (2008) 588 Seven-itemd Fatigue ? Interference BPI-Ie d GLM Mo Mo Mo S S S S S S
Hwang25 (2002) 180 BFI Fatigue (usual)g 24 hours Interference BFI-I d MANOVA Mob Mo Mo Moc Sc S S S
Chang27 (2007) 150 BFI Fatigue (usual)g 24 hours Interference BFI-I d MANOVA b Mob Mo Mo Moc Sc S S
Mendoza14 (1999) 305 BFI Fatigue (worst) 24 hours Interference BFI-I d MANOVA Mob Mob Mo Sc Sc S S
Hwang25 (2002) 180 BFI Fatigue (worst)g 24 hours Interference BFI-I d MANOVA b Mob Mo Sc S S S
Okuyama30 (2003) 252 BFI Fatigue (worst) 24 hours Interference BFI-I d MANOVA Mob Mob Mo Moc Sc S S
Chang27 (2007) 150 BFI Fatigue (worst)g 24 hours Interference BFI-I d MANOVA b Mob Mo Mo Moc Sc S S
Butt6 (2008) 148 Four-itemf Fatigue (worst) Three days Symptom
Scale
FACT-F FACT-F #42 ROC curve CR CR CR CR CR CR
Mendoza29 (2010) 206 BFI Fatigue (worst) 24 hours Interference BFI-I d MANOVA Mob Mob Mo Sc Sc S S
Nausea
Given21 (2008) 588 Seven-itemd Nausea/vomiting ? Interference BPI-Ie d GLM Mo Mo Mo S S S S
Selby10 (2010) 400 ESAS Nausea Now Verbal Scale VRS Mo or S ROC curve Mo S S S S S S
Depression
Vignaroli24 (2006) 216 ESAS Depression ? Symptom
Scale
HADS HADS-D $8 ROC curve CR CR CR CR CR CR CR CR CR
Given21 (2008) 588 Seven-itemd Depression ? Interference BPI-Ie d GLM Mo Mo S S S S S S S
Selby10 (2010) 400 ESAS Depression Now Verbal Scale VRS Mo or S ROC curve Mo Mo Mo S S S S
Anxiety
Vignaroli24 (2006) 216 ESAS Anxiety ? Symptom
Scale
HADS HADS-A $8 ROC curve CR CR CR CR CR CR CR CR CR
Given21 (2008) 588 Seven-itemd Anxiety ? Interference BPI-Ie d GLM Mo Mo S S S S S
Selby10 (2010) 400 ESAS Anxiety Now Verbal Scale VRS Mo or S ROC curve Mo Mo S S S S
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multiple models were tested to determine cut
points, with Li et al.17 testing most extensively.
Two other studies used an ROC curve with the
interference items of the BPI6 or a verbal
scale10 as a reference. Thirteen cut points
were calculated for moderate pain or clinically
relevant pain (range CP2eCP5), with CP5
most frequently being recommended as the
optimal cut point.5,10,17,19,20,22,23,28 Ten cut
points were suggested for severe pain (range
CP5eCP8), with CP7 presented as the optimal
cut point most frequently5,10,17,28 (Table 2).
We found no clear differences in cut points
between studies asking for different types of
pain intensity (present, average, or worst
pain) (Table 2).
Tiredness. Ten studies published cut points on
an NRS for tiredness.5,6,14,18,21,25e27,29,30 The
question on tiredness was formulated as worst
fatigue,6,14,25,27,29,30 usual fatigue,25,27 fa-
tigue,18,21,26 or tiredness.10 Six studies used
a MANOVA6,14,25,27,29,30 and one study
a GLM21 with the interference items of the
BFI as reference. In all studies that determined
the cut point using a MANOVA,6,14,25,27,29,30
conclusions on the optimal cut point were
based on the analyses of two possible cut points
only (Table 2). The other studies used an ROC
curve with the Functional Assessment of Cancer
Therapy-Fatigue subscale,6,26 the interference
items of the BFI,18 or a verbal scale10 as a refer-
ence. Twelve cut points were proposed for mod-
erate tiredness or clinically relevant tiredness
(range CP2eCP6),6,10,14,18,21,25e27,29,30 with
CP4 being found as the optimal cut point
most frequently.14,26,27,29,30 Nine cut points
were proposed for severe tiredness (range
CP5eCP8),10,14,21,25,27,29,30 with CP714,25,29
and CP810,27,30 being recommended as the op-
timal cut points most frequently. We could not
investigate if there were differences in cut
points between studies asking for different
types of tiredness intensity (i.e., usual or worst
fatigue) because only two studies asked for
usual fatigue.
Nausea. Two studies assessed cut points on an
NRS for nausea, using an ROC curve10 or
a GLM.21 The study that used the severity of
nausea expressed on a verbal scale as reference
reported CP4 for moderate nausea and CP5
1090 Vol. 45 No. 6 June 2013Oldenmenger et al.for severe nausea.10 The other study, which de-
termined the cut point using the interference
of nausea in daily life, found CP4 and CP7 to
be the optimal cut points for moderate and se-
vere nausea, respectively21 (Table 2).
Depression. Three studies published cut
points on an NRS for depression.10,21,24 Two
studies used an ROC curve with the depression
subscale of the Hospital Anxiety and Depres-
sion Scale 24 or a verbal scale10 as a reference.
One other study calculated the cut point using
the interference of depression with daily life in
a GLM.21 Cut points for moderate/clinically
relevant depression were CP221,24 or CP4.10 Se-
vere depression was represented with CP421
and CP710 (Table 2).
Anxiety. Three studies assessed cut points on
an NRS for anxiety.10,21,24 Two studies calcu-
lated the sensitivity per cut point using the
anxiety subscale of the Hospital Anxiety and
Depression Scale (clinically relevant CP2)24
or using a verbal scale (moderate CP5),10
whereas the third study determined the opti-
mal cut point using the interference of anxiety
with daily life in a GLM (moderate CP4).21 Se-
vere anxiety was indicated with CP621 or CP710
(Table 2).
Drowsiness. One study determined a cut point
on an NRS for drowsiness based on the severity
of drowsiness as measured with a verbal scale.
Moderate drowsiness was reflected best by
CP5, and severe drowsiness was indicated by
CP710 (Table 2).
Appetite. Three studies reported cut points on
an NRS for appetite.6,10,21 The question on ap-
petite was formulated as ‘‘appetite loss,’’6 ‘‘loss
of appetite,’’10 or ‘‘poor appetite.’’21 Two stud-
ies calculated the sensitivity per cut point using
the Functional Assessment of Anorexia/Ca-
chexia Therapy (clinically relevant CP6)6 or
using a verbal scale (moderate CP5),10 whereas
the other study calculated the optimal cut
point using the interference of poor appetite
with daily life in a GLM (moderate CP4).21
Two studies that determined a cut point for se-
vere appetite loss reported CP710,21 (Table 2).
Well-Being. Only one study determined a cut
point on an NRS for well-being using anROC curve with a verbal scale as reference.
Moderate impairment of well-being corre-
sponded best with an NRS score of 6 and se-
vere impairment of well-being corresponded
best with an NRS score of 7 or higher10
(Table 2).
Shortness of Breath. Two studies assessed cut
points on an NRS for shortness of breath.10,21
The study that used the severity of shortness
of breath expressed on a verbal scale as refer-
ence reported CP4 for moderate shortness of
breath and CP6 for severe shortness of
breath.10 The other study, which determined
the cut point using the interference of dys-
pnea in daily life in a GLM, found CP3 and
CP7 to be the optimal cut points for moderate
and severe dyspnea, respectively21 (Table 2).Discussion
Based on this review, there is not sufficient
evidence for recommending the same cut
point for all symptoms of the ESAS question-
naire. The level of evidence of the optimal
cut point differs per symptom. The most evi-
dence exists for cut points for pain and tired-
ness. Concerning pain, there is consensus for
CP5 as the cut point for moderate pain and,
to a lesser extent, for CP7 as the cut point
for severe pain. This implies that mild pain is
reflected by NRS scores 1e4, moderate pain
by NRS scores 5e6, and severe pain by NRS
scores 7e10. For moderate tiredness, CP4
seems to be the most appropriate cut point.
For severe tiredness, the evidence is ambigu-
ous; both CP7 and CP8 are suggested fre-
quently. There is conflicting evidence for cut
points on the symptoms depression, anxiety,
and appetite. For these symptoms, we found
three or four studies with inconsistent results
per symptom. A lack of evidence exists for
cut points for nausea, shortness of breath,
and well-being. Possible cut points for these
symptoms were only studied once or twice.
Determination of the optimal cut point de-
pends on the purpose of the test in a specific
context, as well as the costs of misses and false
alarms. In research and quality assessment of
care, one usually aims for optimal accuracy
when using a screening measure such as the
NRS. In daily practice, clinicians who screen
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generally aim to minimize the amount of
false-negative test results. In this context, symp-
tom screening with a brief, easy-to-administer
screening tool is usually followed by a more
comprehensive symptom history to identify pa-
tients who actually experience clinically rele-
vant burden. The present review showed that
few existing studies have recommended a cut
point below 4. Therefore, we argue that using
CP4 as a cut point for further screening of
symptoms will result in identifying most pa-
tients with clinically relevant burden.
The interpretation of the results of this re-
view is hampered by the limited comparability
of the studies included because the patients in
these studies varied greatly in tumor type, dis-
ease stage, and treatment received. The com-
parability of the studies also is limited by the
heterogeneity in the symptom assessment
questionnaires used, which, for instance, dif-
fered in the wording of the probe question
and recall time. In addition, the studies varied
in the type of symptom intensity asked for
(e.g., worst, usual, or current) or they did
not specify this (Table 2). Besides this, the
studies differed in the reference questionnaire
used, the cut point used on the reference ques-
tionnaire, the number of possible cut points
explored, and the method used to determine
cut points (Tables 1 and 2).
The interpretation of the results of this
study also is complicated by differences in
the quality of the included studies. For exam-
ple, several studies explored only one
optional cut point for a distinction betweenTable 3
Advantages and Disadvantages of the Variou
Determination of
Cut Points Using Advantages
Daily interference - Gives insight in symptom-related
impairments in daily activities
- No cut point needed on referen
questionnaire
Other symptom-related
questionnaire
- Sensitivity and specificity of cut
points can be calculated
- Facilitates comparison with other
questionnaires
Symptom intensity on verbal
rating scale (none, mild,
moderate, severe)
- Professionals’ prejudices not nee
for determination of cut points
- Fits with the subjective nature of
symptomstwo categories of pain or fatigue and we can-
not rule out that the potential cut point
above5,25,27,28 or below14,25,29,30 the studied
cut point has better characteristics. Unfortu-
nately, there are no quality assessment tools
for observational studies that are sufficiently
validated.31 Moreover, there are no quality as-
sessment tools available that contain criteria
on prerequisites for a reliable assessment of
optimal cut points. Therefore, we decided to
describe several aspects of study quality in the
Results section and in Tables 1 and 2 instead
of performing a quantitative quality assess-
ment with a non-validated tool.
In this review, we identified three methods
to determine cut points: based on daily inter-
ference, based on another symptom-related
questionnaire, and based on verbal rating of
symptom severity (Table 3). Every method
had its advantages and disadvantages, and it
is not clear which method is most suitable to
determine the optimal cut point. In the fu-
ture, thinking aloud studies32 have to be per-
formed to investigate whether patients rate
their symptom intensity on the NRS mainly
on the basis of perceived disabilities caused
by that particular symptom (daily interfer-
ence) or by word descriptors of the symptom
intensity (mild/moderate/severe). More in-
sight into the cognitive processes underlying
the scores on the questionnaires will help to
determine whether cut points should be deter-
mined based on the interference of a certain
symptom with daily life or based on the subjec-
tive severity on a verbal scale. Also, we must
investigate whether various approaches tos Methods to Determine Cut Points
Disadvantages
ce
- Difficult for patients to discriminate which
symptom causes impairments in daily life in
case of suffering from multiple symptoms
- Does not take patients’ opinion on acceptability
of certain symptom scores into account
- Assumption needed on cut point on reference
lists because of lack of gold standards
- Does not take patients’ opinion on acceptability
of certain symptom scores into account
- Does not give insight in symptom-related
impairments in daily activities
ded - Does not give insight in symptom-related
impairments in daily activities
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result in different cut points.
Most importantly, in future research, cut
points should be reported unambiguously.
Fourteen of the 18 included articles described
the cut points as boundaries of the created
categories. The four other articles reported
the ranges of the categories created,18,27,29,30
without mentioning the actual cut point. Six
articles, all pain literature, described upper
boundaries of a category,5,17,19,20,22,23 whereas
eight articles reported the lower boundaries
of a category.6,10,14,21,24e26,28 Uniformity in re-
porting cut points is important to avoid confu-
sion. For example, the NCCN guideline ‘‘Adult
Cancer Pain’’ categorized mild pain as 1e3,9
referring to Serlin et al.5 In the original study,
however, Serlin et al.5 categorized mild pain
as 1e4.
Little is known about the validity of cut points
in different situations, for example, in thediffer-
ent stages of cancer or for inpatients and outpa-
tients. Besides this, it is possible that the type of
symptom intensity asked for (e.g., worst, usual,
or current) will affect the cut points. Moreover,
cut points could differ depending on the patho-
physiology of the symptom (e.g., nociceptive
pain and neuropathic pain; physical fatigue
and mental fatigue). Furthermore, it is unclear
whether cut points are stable over time. It is
conceivable that cut points change after a long
duration of suffering of a certain symptom. Pro-
spective studies are needed to determine the
factors that influence the cut points.
In conclusion, cut points are frequently used
in clinical practice and scientific research. In
this review, we found some evidence on cut
points for pain (moderate pain CP5 and severe
pain CP7) and fatigue (moderate fatigue CP4).
Until there is more evidence on the optimal cut
points, we should hold back in using a certain
cut point in quality indicators and be cautious
about strongly recommending a cut point in
guidelines. In daily clinical practice, symptom
scores$4 should trigger amore comprehensive
symptomassessment to properly identify the pa-
tients with clinically relevant symptom burden.Disclosures and Acknowledgments
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